<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03351114</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00086947</org_study_id>
    <nct_id>NCT03351114</nct_id>
  </id_info>
  <brief_title>Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea</brief_title>
  <official_title>Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to determine the safety and clinical efficacy of crisaborole 2%&#xD;
      ointment in the treatment of morphea.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2, pilot, proof-of-concept, open label, single arm prospective study to assess the&#xD;
      safety, tolerability and efficacy of using crisaborole 2% ointment for adult morphea.&#xD;
      Patients identified by their physician, nurse, or other member of their clinical care team as&#xD;
      meeting criteria for the study will be asked to apply crisaborole 2% ointment, twice daily,&#xD;
      on affected plaques for 12 weeks. A 4 mm skin punch biopsy will be performed at baseline and&#xD;
      at 12 weeks, on the same affected plaque. Dermal thickness will be measured and compared&#xD;
      before and at the end of treatment. Patients will have a clinical assessment at baseline and&#xD;
      at weeks 4, 8 and 12. After week 12, patients who need further treatment will undergo&#xD;
      standard of care treatment as determined by their primary dermatologist. Physician and&#xD;
      patient reported assessment and skin imaging will be performed at baseline, week 4, 8 and 12,&#xD;
      and at week 20. Photography will also be performed at baseline and week 12. An optional post&#xD;
      treatment follow-up will be performed at week 20.&#xD;
&#xD;
      Medication will be provided free of charge by Pfizer, as part of the grant that is funding&#xD;
      this study. These will be dispensed by the study group at baseline and during the subsequent&#xD;
      clinic visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">March 10, 2020</completion_date>
  <primary_completion_date type="Actual">March 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Had a Reduction in Dermal Thickness of Sentinel Plaque</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change in dermal thickness on skin biopsy. A sentinel plaque will be selected at baseline. A 4 mm skin punch biopsy will be performed at baseline and at 12 weeks, on the same affected plaque.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Reduction in DIET Score of Sentinel Plaque</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The DIET (Dyspigmentation, Induration, Erythema, and Telangiectasias) score is a physician-assessed, previously validated score. Range is 0-12, and a higher score denotes increased activity or severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Reduction in LoSCAT Score</measure>
    <time_frame>Baseline,12 weeks</time_frame>
    <description>LoSCAT (Localized Scleroderma Cutaneous Assessment Tool ) score is a physician-assessed, previously validated score. It has 2 components, the LoSSI (localized scleroderma skin severity index, range 0-162), which measures disease activity, and LoSDI (localized scleroderma damage index, range 0-216). The higher the number, the higher the disease activity and damage, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Reduction in Skindex-29 Score</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Skindex-29 is a health-related quality of life score; minimum score 30, maximum 150. Lower score indicates a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dermal Thickness of Sentinel Plaque by Ultrasonography</measure>
    <time_frame>Baseline, 4, 8 and 12 weeks, optional at 20 weeks</time_frame>
    <description>B-Mode ultrasonographic imaging will be utilized to measure dermal thickness of the sentinel plaque</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Morphea</condition>
  <arm_group>
    <arm_group_label>Crisaborole 2% ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crisaborole 2% ointment applied to affected skin twice per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crisaborole</intervention_name>
    <description>Apply Crisaborole 2% ointment to affected skin twice per day.</description>
    <arm_group_label>Crisaborole 2% ointment</arm_group_label>
    <other_name>Eucrisa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. &gt;= 18 years of age&#xD;
&#xD;
          2. Clinical diagnosis of morphea.&#xD;
&#xD;
          3. &lt;20% Total body surface area involvement.&#xD;
&#xD;
          4. Does not require systemic immunosuppressive therapy for morphea.&#xD;
&#xD;
          5. No immunosuppressive systemic therapy 1 month prior to starting the study&#xD;
             (methotrexate, mycophenolate mofetil, azathioprine, cyclosporine, cyclophosphamide,&#xD;
             prednisone &gt;=10 mg PO daily).&#xD;
&#xD;
          6. No immunomodulating topical therapy (topical steroids or topical calcineurin&#xD;
             inhibitor), and no topical vitamin D analogue, 2 weeks prior to starting study.&#xD;
&#xD;
          7. No allergy to crisaborole or vehicle.&#xD;
&#xD;
          8. No known renal disease&#xD;
&#xD;
          9. Able to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:Subjects fulfilling any of the following criteria are not eligible for&#xD;
        inclusion in this study.&#xD;
&#xD;
          1. Clinical diagnosis of depression or history of suicidal ideation.&#xD;
&#xD;
          2. Pregnant or breastfeeding women, with pregnant women being defined as the state of a&#xD;
             female after conception until the termination of gestation, confirmed by a positive&#xD;
             urine human chorionic gonadotropin (hCG) laboratory test. Women with a positive urine&#xD;
             hCG at any time during the study will be withdrawn from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adela Cardones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke UMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <results_first_submitted>March 10, 2021</results_first_submitted>
  <results_first_submitted_qc>March 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 1, 2021</results_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Morphea, Localized Scleroderma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03351114/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Crisaborole 2% Ointment</title>
          <description>Crisaborole 2% ointment applied to affected skin twice per day.&#xD;
Crisaborole: Apply Crisaborole 2% ointment to affected skin twice per day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Crisaborole 2% Ointment</title>
          <description>Crisaborole 2% ointment applied to affected skin twice per day.&#xD;
Crisaborole: Apply Crisaborole 2% ointment to affected skin twice per day.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" lower_limit="31" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Had a Reduction in Dermal Thickness of Sentinel Plaque</title>
        <description>Change in dermal thickness on skin biopsy. A sentinel plaque will be selected at baseline. A 4 mm skin punch biopsy will be performed at baseline and at 12 weeks, on the same affected plaque.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crisaborole 2% Ointment</title>
            <description>Crisaborole 2% ointment applied to affected skin twice per day.&#xD;
Crisaborole: Apply Crisaborole 2% ointment to affected skin twice per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had a Reduction in Dermal Thickness of Sentinel Plaque</title>
          <description>Change in dermal thickness on skin biopsy. A sentinel plaque will be selected at baseline. A 4 mm skin punch biopsy will be performed at baseline and at 12 weeks, on the same affected plaque.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Reduction in DIET Score of Sentinel Plaque</title>
        <description>The DIET (Dyspigmentation, Induration, Erythema, and Telangiectasias) score is a physician-assessed, previously validated score. Range is 0-12, and a higher score denotes increased activity or severity.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crisaborole 2% Ointment</title>
            <description>Crisaborole 2% ointment applied to affected skin twice per day.&#xD;
Crisaborole: Apply Crisaborole 2% ointment to affected skin twice per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Reduction in DIET Score of Sentinel Plaque</title>
          <description>The DIET (Dyspigmentation, Induration, Erythema, and Telangiectasias) score is a physician-assessed, previously validated score. Range is 0-12, and a higher score denotes increased activity or severity.</description>
          <units>percentage of reduction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Reduction in LoSCAT Score</title>
        <description>LoSCAT (Localized Scleroderma Cutaneous Assessment Tool ) score is a physician-assessed, previously validated score. It has 2 components, the LoSSI (localized scleroderma skin severity index, range 0-162), which measures disease activity, and LoSDI (localized scleroderma damage index, range 0-216). The higher the number, the higher the disease activity and damage, respectively.</description>
        <time_frame>Baseline,12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crisaborole 2% Ointment</title>
            <description>Crisaborole 2% ointment applied to affected skin twice per day.&#xD;
Crisaborole: Apply Crisaborole 2% ointment to affected skin twice per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Reduction in LoSCAT Score</title>
          <description>LoSCAT (Localized Scleroderma Cutaneous Assessment Tool ) score is a physician-assessed, previously validated score. It has 2 components, the LoSSI (localized scleroderma skin severity index, range 0-162), which measures disease activity, and LoSDI (localized scleroderma damage index, range 0-216). The higher the number, the higher the disease activity and damage, respectively.</description>
          <units>percentage of reduction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LoSSI (Activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LoSDI (Damage)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Reduction in Skindex-29 Score</title>
        <description>Skindex-29 is a health-related quality of life score; minimum score 30, maximum 150. Lower score indicates a better quality of life.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crisaborole 2% Ointment</title>
            <description>Crisaborole 2% ointment applied to affected skin twice per day.&#xD;
Crisaborole: Apply Crisaborole 2% ointment to affected skin twice per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Reduction in Skindex-29 Score</title>
          <description>Skindex-29 is a health-related quality of life score; minimum score 30, maximum 150. Lower score indicates a better quality of life.</description>
          <units>percentage of reduction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Dermal Thickness of Sentinel Plaque by Ultrasonography</title>
        <description>B-Mode ultrasonographic imaging will be utilized to measure dermal thickness of the sentinel plaque</description>
        <time_frame>Baseline, 4, 8 and 12 weeks, optional at 20 weeks</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Crisaborole 2% Ointment</title>
            <description>Crisaborole 2% ointment applied to affected skin twice per day.&#xD;
Crisaborole: Apply Crisaborole 2% ointment to affected skin twice per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Dermal Thickness of Sentinel Plaque by Ultrasonography</title>
          <description>B-Mode ultrasonographic imaging will be utilized to measure dermal thickness of the sentinel plaque</description>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Crisaborole 2% Ointment</title>
          <description>Crisaborole 2% ointment applied to affected skin twice per day.&#xD;
Crisaborole: Apply Crisaborole 2% ointment to affected skin twice per day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Adela R. Cardones</name_or_title>
      <organization>Duke University</organization>
      <phone>9196843110</phone>
      <email>adela.cardones@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

